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Daniel J. Weisdorf1Data on pretransplantation minimal residual disease (MRD) and outcomes of umbilical cord blood transplan-
tation (UCBT) are limited. Out of the 143 patients with acute lymphoblastic leukemia (ALL) who underwent
UCBTat the University of Minnesota between 2004 and 2010, we evaluated 86 patients with available MRD
assessment data by 4- and 8-color flow cytometry analysis immediately before transplantation. Ten patients
(11.6%) were MRD-positive, and 76 were MRD-negative (88.4%). Most of the patients (82%) received mye-
loablative conditioning. GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. In multi-
variate analysis, age, disease status (complete remission [CR] 1 versus CR2/CR3), disease group
(precursor B cell ALL versus Philadelphia chromosome–positive ALL versus T cell ALL), and time to trans-
plantation had no impact on relapse. Patients with MRD before UCBT had a greater incidence of relapse at 2
years (relapse rate, 30%; 95% confidence interval [CI], 4%-56%) and lower 3-year disease-free survival (30%;
95% CI, 7%-58%) compared with those without MRD (relapse rate, 16%; 95% CI, 8%-25%; P5 .05; disease-
free survival, 55%; 95% CI, 43%-66%; P5 .02). Our data suggest that in patients with ALL, achieving an MRD-
negative state before UCBT improves outcomes.
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Relapse and transplantation-related mortality
(TRM) continue to be the greatest hurdles facing pa-
tients who undergo allogeneic hematopoietic cell
transplantation (allo-HCT) for acute lymphoblastic
leukemia (ALL) [1-4]. Identifying the patients at
greatest risk for post-HCT failure is critical to the
application of risk-adapted therapy. Recent pediatric
ALL studies suggest that minimal residual disease
(MRD) detected immediately before allo-HCT is an
independent predictor of the risk of relapse [5-9];
however, data on pretransplantation MRD in adults
undergoing allo-HCT for ALL are limited and in-
consistent [10-14]. In the prospective UKALL XII/
ECOG2993 trial, the presence of MRD evaluated
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associated with a significantly higher rate of
treatment failure compared with the absence of
MRD (relapse-free survival, 25% versus 77%).
Interestingly, in that study, MRD detected before
allo-HCT did not adversely affect outcomes for recip-
ients in first complete remission (CR) [11]. In another
study, MRD status as assessed by semiquantitative im-
munoglobulin gene analysis early after allo-HCT was
more strongly associated with a high relapse rate com-
paredwithMRD status assessed before allo-HCT [13].
Similarly, Bassan et al. [10] prospectively studiedMRD
by real-time quantitative polymerase chain reaction
(PCR) using leukemia-specific probes as a decision
tool for maintenance therapy (for MRD-negative pa-
tients) versus HCT (for MRD-positive patients) and
found clearly poorer outcomes in the MRD-positive
patients; however, a proportion of the MRD-positive
patientswere effectively rescuedbyHCT.Collectively,
these data suggest the possibility that allografts can
potentially overcome the adverse prognostic impact
of MRD.
In some previous studies, patient-specific primers
were needed to identify the clonotypic breakpoint
associated with leukemia-specific unique B cell
immunoglobulin sequences and T cell receptor
rearrangements [5-14]. Recent data support the use
of multicolor flow cytometry to identify residual
leukemic blasts by detecting an aberrant surface
immunophenotype associated with ALL, but reports
on the use of multicolor flow cytometry to detect
MRD status before transplantation are limited
[15-17]. There are no reports evaluating the effect of
pre-HCT MRD status on post-HCT relapse in pa-
tients who underwent allo-HCT with umbilical cord
blood as the stem cell source. Consequently, we stud-
ied the prognostic value of pretransplantation MRD
status as determined by multicolor flow cytometry in
children and adults with ALL who underwent
UCBT in our institution.METHODS
Patients and Treatment Protocol
Using prospectively collected data from the Uni-
versity of Minnesota’s Blood and Marrow Transplan-
tation Database, we reviewed consecutive patients
who underwent UCBT for ALL between 2004 and
2010. The transplantation protocols were approved
by the University of Minnesota’s Institutional Review
Board, and each patient or a parent/guardian provided
written informed consent for therapy and prospective
data collection in our transplantation database. Condi-
tioning regimens, immune suppression, UCB graft se-
lection, and supportive care have been reported
previously [18,19]. In brief, the myeloablative (MA)conditioning regimen consisted of cyclophosphamide
60 mg/kg i.v. for 2 days, fludarabine 25 mg/m2 i.v.
for 3 days, and total body irradiation (TBI) 165 cGy
twice daily for 4 days [18]. Reduced-intensity condi-
tioning (RIC) consisted of cyclophosphamide 50 mg/
kg/day i.v. for 1 day, fludarabine 40 mg/m2 i.v. for 5
days, and 200 cGy of TBI [19]. All patients received
cyclosporine (on days 23 to 180) and mycophenolate
mofetil (on days 23 to 130) for GVHD prophylaxis.
Immunophenotypic Evaluation of MRD
Out of 143 consecutive UCBTs for ALL, we iden-
tified 136 patients who were in complete morphologi-
cal remission (CR) before transplantation. Seven
patients were excluded due to the morphological pres-
ence of leukemia. All patients underwent marrowmor-
phological evaluation, and 86 patients underwent
multiparameter flow cytometry assessment within 30
days before UCBT. All pretransplantation immuno-
phenotypic files were centrally reviewed by 2 hemato-
pathologists (S.Y. and T.P.S.) at the University of
Minnesota. MRD for B lymphoblasts was assessed by
multiparameter flow cytometry using 4- or 8-color
analysis with combinations of antibodies for CD10,
CD19, CD20, CD22, CD34, CD38, CD45, CD58,
kappa, and lambda using FITC, PE, PerCP-Cy5.5 or
PE-CY5, PE-Cy7, APC, APC-H7, Pacific Blue or
V450, and AmCyan or V500 fluorochromes. T lym-
phoblasts were evaluated using combinations of anti-
bodies to CD2, CD3, CD4, CD5, CD7, CD8,
CD34, and CD45. All antibodies were obtained from
BD Biosciences (San Jose, CA), except CD58 in APC
(BeckmanCoulter, Brea,CA), and kappa inPE, lambda
in FITC, andCD19 in Pacific Blue (Dako, Carpinteria,
CA). In all specimens except those limited by low cellu-
larity, 100,000 events were collected and analyzed.
Combined CD45 and side-scatter gating were used to
identify blast populations after nonviable cells and dou-
blets were excluded. Analyses were performed using
FCS Express software (De Novo Software, Los
Angeles, CA). In accordance with previous studies
[15], we identified residual lymphoblasts based on an
aberrant phenotype comparedwith the normalmatura-
tion pattern of hematogones. Sensitivity for detection
of lymphoblasts ranged from 0.03% to 0.1%, with
higher sensitivities seen with 8-color flow cytometry.
Statistical Analysis
Patient and disease characteristics were compared
in MRD-positive and MRD-negative patients using
the nonparametric Wilcoxon test for continuous
factors and Pearson’s c2 test for categorical factors.
All patients were followed until death or last follow-
up. The Kaplan-Meier method was used to estimate
overall survival (OS) and disease-free survival (DFS),
and the log-rank test was used to compare these values
Table 1. MRD Status before UCBT in 86 Patients with ALL
Factor MRD-Positive MRD-Negative
P
Value
Number of patients 10 76
Age at UCBT, years, median (range) 20 (6-41) 21 (1-63)
Age group, years, n (%) .54
0-10 3 (30) 17 (22)
10-20 2 (20) 18 (24)
20-45 5 (50) 29 (38)
Biol Blood Marrow Transplant 18:958-973, 2012 965UCBT for ALL and MRD[21].Cumulative incidencewas used to estimate relapse
and TRM [22]. The proportional hazards model of
Fine and Gray was used to assess independent factors
on relapse. Factors considered in regression analysis
were presence of MRD, ALL subtype, recipient age,
disease status at transplantation, cytogenetics, time
from diagnosis to transplantation, and recipient cyto-
megalovirus (CMV) status.$45 0 12 (16)
Sex, n (%) .75
Male 5 (50) 42 (55)
Female 5 (50) 34 (45)
Remission status at HCT, n (%) .08
CR1 2 (20) 40 (53)
CR2 7 (70) 26 (34)
CR3 1 (10) 10 (13)
Patient CMV serostatus, n (%) .66
Positive 6 (60) 40 (53)
Negative 4 (40) 36 (47)
Cytogenetics, n (%) .56
Normal cytogenetics 0 9 (12)
Ph+ 2 (20) 25 (33)
Other unfavorable 2 (20) 17 (22)
Hyperdiploid 2 (20) 9 (12)
Hypodiploid 0 3 (4)
Other 3 (30) 10 (13)
NA 1 (10) 3 (4)
Conditioning intensity, n (%) .37
MA 9 (90) 59 (78)
RIC 1 (10) 17 (22)
Graft source, n (%) .31
Single UCB 5 (50) 19 (25)
Double UCB 5 (50) 57 (75)
Total nucleated cell dose,  107/kg,
median (range)
3.9 (2.4-6.3) 4.0 (2.2-4.9) .91
NA indicates not available.RESULTS
Patient and Transplantation Characteristics
The study population comprised 46 adults (54%)
and 40 children (age#20 years) (46%) who underwent
single-unit UCBT (27%) or double-unit UCBT
(73%) between 2004 and 2010. Of these 86 patients,
10 had detectable MRD (MRD-positive group) and
76 had no immunophenotypic evidence of an aberrant
lymphoblast population in a pretransplantation bone
marrow biopsy specimen (MRD-negative group).
Precursor B cell ALL (n 5 76) was more common
than T cell ALL (n 5 10). The most common molec-
ular or cytogenetic abnormality was Philadelphia
chromosome–positive (Ph1) ALL (n 5 27), followed
by other unfavorable cytogenetics (n 5 19), hyperdi-
ploid (n 5 11), normal karyotype (n 5 9),
hypodiploid (n 5 3), and other (n 5 13) (Table 1).
The median time from diagnosis to transplantation
was 31.6 months in the children and 6.1 months in
the adults. The median follow-up among survivors
was 3.9 years (range, 0.5-11.8 years).
Themajority of patients receivedMA conditioning
(n 5 68; 79%), with RIC used in patients age .45
years and patients with compromised organ function.
More adults than children received a double UCB
graft (90% versus 27%; P 5 .01). UCB units were
HLA-matched at HLA-A, -B, and -DRB1 as described
previously [18,19], and units were matched at 4/6 and
5/6 loci in 65% and 28% of adults, respectively, versus
29% and 53% of children (P5 .01). The median total
nucleated cell (TNC) dose was 3.95  107/kg (range,
1.1-4.89  107/kg), and the median CD34 cell dose
in UCB grafts was 4.7  105/kg (range, 0.6-8.4 
105/kg). Characteristics of the MRD-positive and
MRD-negative groups are summarized in Table 1.
Impact of MRD on the Risk of Relapse after
UCBT
All MRD-positive patients (5 children and 5
adults) had a precursor B lineage phenotype, and the
majority were in CR2 (n 5 7) or CR1 (n 5 2)
(Table 2). Nine patients received MA conditioning,
and 5 received a double-unit UCB graft. Two patients
had Ph1 ALL, both of whom died of early TRM. Nei-
ther of these patients received a tyrosine-kinase inhib-
itor posttransplantation. The time from diagnosis totransplantation was similar in the MRD-positive and
MRD-negative groups (1.2 years versus 0.8 years;
P 5 .76).
The overall cumulative incidence of leukemia re-
lapse at 2 years was 18% (95%CI, 9%-26%). Notably,
theMRD-positive patients had a 2-fold greater risk for
relapse compared with the MRD-negative patients
(30% [95% CI, 4%-56%] versus 16% [95% CI, 8%-
25%];P5 .05) (Figure 1B). Themedian time to relapse
was 2.4 months (range, 0.66-6.7 months) in the MRD-
positive patients and 8.4 months (range, 1.4-22.4
months) in the MRD-negative patients (P 5 .07). In
multivariate analyses, the relapse rate was not signifi-
cantly affected by disease status at transplantation
(CR1 versus CR2/CR3: relative risk [RR], 0.89; 95%
CI, 0.23-3.43;P5 .86), ALL subtype (RR, 1.00 for pre-
cursor B cell ALL versus 1.07 for T cell ALL versus
0.44 for Ph1 ALL; P 5 .44, P 5 .92), sex (female:
RR, 0.64; P5 .50), time from diagnosis to transplanta-
tion (.11 months: RR, 1.23: P5 .72), or patient CMV
status (CMV-positive: RR, 1.57; P5 .47). MRD status
remained an independent predictor of relapse in a re-
duced regression model (MRD-negative: RR, 0.2;
P 5 .04). The 3-year DFS and OS for the MRD-
positive patients were 30% (95% CI, 7%-58%) and
40% (95% CI, 12%-67%), respectively, significantly
Table 2. Characteristics of the Patients with MRD
Patient
Age,
Years
Disease
Status
MRD Level,
Blast %
Conditioning
Intensity
Number of
UCB Units
Post-HCT
Status
1 17 CR2 2 MA 2 Alive
2 6 CR2 0.5 MA 1 Alive
3 27 CR2 0.1-0.2 MA 2 Alive
4 35 CR1 0.08 MA 2 TRM
5 9 CR3 1 MA 1 Relapse
6 41 CR2 0.3 RIC 1 TRM
7 31 CR2 1.4 MA 2 TRM
8 7 CR2 2 MA 1 Relapse
9 11 CR2 0.9 MA 1 Relapse
10 24 CR1 0.1 MA 2 TRM
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55%; 95% CI, 43%-66%; P5 .02; OS, 55%; 95% CI,
42%-66%; P5 .09) (Figure 1A). In univariate analysis,
the 3-year DFS was also affected by age and was partic-
ularly promising in children age\10 years (80%; 95%
CI, 55%-92%) compared to children age 10-18 years
(54%; 95% CI, 30%-73%) and adults (38%; 95%
CI, 22%-54%) (P 5 .03). In multivariate analysis,
MRD-negative status was the sole significant inde-
pendent predictor of superior DFS (MRD-negative:
RR, 0.20; 95% CI, 0.05-0.080; P 5 .02). Survival
was unaffected by disease status (CR1 versus CR2/
CR3: RR, 1.59; 85% CI, 0.56-4.53; P 5 .38),
WBC count at diagnosis ($20  103/mL: RR, 1.55;
95% CI, 0.64-3.76; P 5 .34) sex, age, cytogenetic
group, phenotype, and recipient CMV status (data
not shown). We observed a trend toward higher
TRM in the MRD-positive group compared with
the MRD-negative group (40% [95% CI, 11%-
69%] versus 25% [95% CI, 15%-35%]; P 5 .09),
but no difference in the causes of death (data not
shown). Engraftment failure occurred in 1 MRD-
positive patient and in 4 MRD-negative patients.
The cumulative incidents of grade II-IV acute
graft-versus-host disease (GVHD) and chronic
GVHD were 50% (95% CI, 39%-61%) and 15%
(7%-23%), respectively, and were similar in the 2
MRD groups.0.0
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Figure 1. Transplantation outcomes. (A) Three-year DFS in patients with ALL
status.DISCUSSION
The outcomes in this large cohort of ALL patients
who underwent UCBT suggest a promising survival
rate after UCBT, comparable to the rates reported
for matched sibling allo-HCT and unrelated donor
allo-HCT for ALL [1,3,23-25]. Our results also
demonstrate that MRD-positive status before UCBT
is an independent predictor for relapse and confers
inferior DFS. Virtually all relapses in patients with
residual leukemia (MRD-positive) occurred within 6
months posttransplantation, and significantly earlier
than in MRD-negative patients, suggesting that the
kinetics between leukemia regrowth and graft-versus-
leukemia are dynamic and favor relapse in those with
a greater pre-HCTdisease burden.We found a slightly
higher rate of TRM in the MRD-positive patients, but
our small number of patients precludes us from draw-
ing any conclusions regarding potential causes. Our
data do not suggest a high risk of nonengraftment in
MRD-positive patients. Of note, 3 MRD-positive pa-
tients survived long-term after UCBT (2 of whom re-
ceived double UCB units), suggesting that UCB grafts
may have the potential to overcome MRD. These re-
sults support a previous observation of stronger anti-
leukemia potency of double-UCB HCT compared
with single-UCB HCT [18]. These results should be
interpreted with caution, however, given the relatively
low rate of MRD in our cohort. Additional studies are
needed to further evaluate the influence ofMRD status
on UCBT outcomes and to determine the optimal ap-
proach for assessing MRD. We have evaluated a non-
PCR technique using clinical- and laboratory-based
flow cytometry to measure MRD, which has lower
and more variable sensitivity (0.03%-0.1%) compared
with PCR [20]. Although our results reflect the com-
mon clinical practice for MRD monitoring, we advo-
cate further refinement and standardization of
immunophenotypic methods as an essential and infor-
mative measure of remission depth in future ALL
transplantation protocols [26,27].0.0
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by MRD status. (B) Two-year relapse rate in patients with ALL by MRD
Biol Blood Marrow Transplant 18:958-973, 2012 967UCBT for ALL and MRDOur results indicate that novel strategies in UCBT
for patients with ALL should focus on better leukemia
control to induce an MRD-negative state before
transplantation. Routine assessment of MRD status
pre-UCBT by multicolor flow cytometry and the de-
velopment of clinical trials incorporating additional
therapies for patients in CR but with MRD should be
considered. In MRD-positive patients, clinicians will
need to judge whether further therapy before trans-
plantation is likely to render the patient MRD-free
while maintaining his or her status as a suitable trans-
plantation candidate, as well as whether the inclusion
of additional anti-ALL therapies (eg, monoclonal
antibodies, monoclonal antibody–drug conjugates) in
the conditioning regimen [28] or early post-UCBT
modulation of immunosuppression or maintenance
therapy (eg, tyrosine-kinase inhibitor for Ph1 ALL) is
warranted.
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Allison M. Deal,3,4 Cherie H. Dunphy,1,2 Andrew Sharf,4
Thomas C. Shea,2,4,5 Jonathan S. Serody,2,4,5 Stefanie Sarantopoulos2,4,5Patients without chronic graft-versus-host disease (cGVHD) have robust B cell reconstitution and are able to
maintain B cell homeostasis after allogeneic hematopoietic stem cell transplantation (HSCT). To determine
whether B lymphopoiesis differs before cGVHD develops, we examined bone marrow (BM) biopsies for ter-
minal deoxynucleotidyl transferase (TdT) and PAX5 immunostaining early post-HSCTat day 30 when all pa-
tients have been shown to have high B cell activating factor (BAFF) levels. We found significantly greater
numbers of BM B cell precursors in patients who did not develop cGVHD compared with those who devel-
oped cGVHD (median5 44 vs 2 cells/high powered field [hpf]; respectively; P\.001). Importantly, a signif-
icant increase in precursor B cells was maintained when patients receiving high-dose steroid therapy were
excluded (median 5 49 vs 20 cells/hpf; P 5 .017). Thus, we demonstrate the association of BM B cell pro-
duction capacity in human GVHD development. Increased BM precursor B cell number may serve to predict
good clinical outcome after HSCT.
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In the absence of B cell activating factor (BAFF),
normal B cell homeostasis in murine models is not
possible [1]. Early after hematopoietic stem cell trans-
plantation (HSCT), patients have high BAFF levels,
suggesting its vital role in human B cell reconstitution
[2]. Patients who have undergone HSCT have de-
creased total B cells, including memory B cells, associ-
ated with immune deficiency and increased infection
[3-6]. Studies of excess BAFF in chronic graft-versus-
host disease (cGVHD) revealed that a previously
described supernormal ‘‘surge’’ in na€ıve B cell number
after HSCT [7-9] accounted for significantly lower
BAFF/B cell ratios and decreased B cell auto-
reactivity [2,10]. Thus, akin to what has been
demonstrated in mouse models of autoimmunity,
a peripheral na€ıve B cell compartment is critical for
